News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,890 Results
Type
Article (14276)
Company Profile (105)
Press Release (259501)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88289)
Career Advice (466)
Deals (15395)
Drug Delivery (73)
Drug Development (36720)
Employer Resources (50)
FDA (6382)
Job Trends (6233)
News (150724)
Policy (14132)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23327)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6573)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (171)
Cancer (1317)
Cardiovascular disease (151)
Career advice (419)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (150)
Cervical cancer (9)
Clinical research (32023)
Collaboration (725)
Compensation (325)
Complete response letters (33)
COVID-19 (778)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1821)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (80)
Earnings (33465)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (38996)
Executive appointments (528)
FDA (7480)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (428)
Gene editing (70)
Generative AI (18)
Gene therapy (165)
GLP-1 (439)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3578)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (842)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (61)
IPO (5915)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1303)
Medtech (1310)
Mergers & acquisitions (9900)
Metabolic disorders (434)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (37)
Neuroscience (887)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (602)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29744)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8307)
Phase 2 (13521)
Phase 3 (12213)
Pipeline (1904)
Policy (135)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (350)
Real estate (2660)
Recruiting (18)
Regulatory (10958)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (231)
Venture capital (33)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Today (5)
Last 7 days (177)
Last 30 days (734)
Last 365 days (10437)
2026 (951)
2025 (10715)
2024 (12499)
2023 (14246)
2022 (19561)
2021 (20076)
2020 (19037)
2019 (14891)
2018 (11724)
2017 (13889)
2016 (13130)
2015 (15474)
2014 (12419)
2013 (10593)
2012 (11395)
2011 (11923)
2010 (10890)
Location
Africa (319)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20890)
Australia (2688)
California (3178)
Canada (1481)
China (550)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40881)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (349)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2586)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1396)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1448)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (509)
South Carolina (10)
Southern California (1387)
Tennessee (53)
Texas (454)
United States (12670)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,890 Results for "lexicon pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
·
1 min read
Press Releases
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
January 9, 2026
·
3 min read
Press Releases
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
·
6 min read
Pain
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis
Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage development—despite a topline miss in March—is an “improving” regulatory environment for non-addictive options for chronic pain, according to analysts at Jefferies.
September 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
January 22, 2026
·
4 min read
Press Releases
Lexicon Pharmaceuticals to Participate in Two Upcoming December 2025 Investor Conferences
November 26, 2025
·
1 min read
Press Releases
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
November 11, 2025
·
1 min read
Press Releases
Lexicon Announces Proposed Public Offering of Common Stock - January 29, 2026
January 30, 2026
·
4 min read
Press Releases
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
January 30, 2026
·
6 min read
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested.
January 22, 2026
·
2 min read
·
Tristan Manalac
1 of 27,389
Next
